B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$85M
Cap. Flow
-$603M
Cap. Flow %
-18.9%
Top 10 Hldgs %
36.68%
Holding
85
New
17
Increased
26
Reduced
11
Closed
10
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$75.5M
2
SYRE icon
Spyre Therapeutics
SYRE
+$67.4M
3
EXAS icon
Exact Sciences
EXAS
+$62.8M
4
INSP icon
Inspire Medical Systems
INSP
+$52.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$50.1M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$50.9M
2
PCVX icon
Vaxcyte
PCVX
+$27.5M
3
CGEM icon
Cullinan Oncology
CGEM
+$22.7M
4
TRML icon
Tourmaline Bio
TRML
+$20.8M
5
ARGX icon
argenx
ARGX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.98%
2 Miscellaneous 38.71%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ELEV icon
51
DELISTED
Elevation Oncology
ELEV
$6.69M 0.21%
2,477,614
+99,967
+4% +$376K
2024 Q1
1 quarter
HROW icon
52
Harrow
HROW
$1.03B
$6.21M 0.19%
297,188
+171,221
+136% +$2.56M
2023 Q1
5 quarters
LBPH icon
53
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.57M 0.17%
+205,926
New +$4.06M
2024 Q2
0 quarters
LUNG icon
54
Pulmonx
LUNG
$76.4M
$4.77M 0.15%
752,541
– –
2022 Q4
6 quarters
CGEM icon
55
Cullinan Oncology
CGEM
$877M
$3.07M 0.1%
176,173
-1,064,692
-86% -$22.7M
2023 Q2
4 quarters
OM icon
56
Outset Medical
OM
$72.2M
$2.67M 0.08%
46,302
-113,726
-71% -$5.57M
2022 Q4
6 quarters
DBVT icon
57
DBV Technologies S.A. American Depositary Shares
DBVT
$562M
$1.96M 0.06%
488,501
-295,828
-38% -$1.81M
2022 Q4
6 quarters
ETNB icon
58
DELISTED
89bio
ETNB
$1.32M 0.04%
+164,227
New +$1.47M
2024 Q2
0 quarters
ADPT icon
59
Adaptive Biotechnologies
ADPT
$4.07B
– –
-1,357,490
Closed -$4.36M –
ARQT icon
60
Arcutis Biotherapeutics
ARQT
$3.34B
– –
-1,300,000
Closed -$12.9M –
BCRX icon
61
BioCryst Pharmaceuticals
BCRX
$2.05B
– –
-3,379,577
Closed -$17.2M –
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$10.7B
– –
-218,896
Closed -$19.1M –
GPCR icon
63
Structure Therapeutics
GPCR
$1.57B
– –
-435,823
Closed -$18.7M –
ITOS icon
64
DELISTED
iTeos Therapeutics
ITOS
– –
-1,162,374
Closed -$15.9M –
MLYS icon
65
Mineralys Therapeutics
MLYS
$1.86B
– –
-1,147,154
Closed -$14.8M –
OLMA icon
66
Olema Pharmaceuticals
OLMA
$590M
– –
-704,344
Closed -$7.97M –
TRML icon
67
DELISTED
Tourmaline Bio
TRML
– –
-906,820
Closed -$20.8M –
DCPH icon
68
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-609,643
Closed -$9.59M –
1 2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2024 Portfolio in Review

As of Q2 2024, Braidwell held 85 positions worth $3.19B, up 2.7% from $3.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $603M in Q2 2024, closing 10 positions and reducing 11 holdings. Its most notable exit was Tourmaline Bio, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Exact Sciences worth $48.2M.

  • Braidwell's largest Q2 2024 buy was Exact Sciences: 1,141,678 shares worth $48.2M.
  • Braidwell added most to CG Oncology in Q2 2024, an estimated $75.5M increase.
  • Braidwell's biggest Q2 2024 reduction was Transmedics, cutting an estimated $50.9M.
  • Braidwell fully exited Tourmaline Bio in Q2 2024, selling an estimated $20.8M.
  • Braidwell's ten largest holdings make up 37% of its $3.19B portfolio in Q2 2024.
  • Braidwell opened 17 new positions and closed 10 in Q2 2024.
  • Braidwell's portfolio value rose 2.7% quarter-over-quarter to $3.19B.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.